Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vivus: into single digits -- Ignore unavailable to you. Want to Upgrade?

To: MIKE DUBIS who wrote (579)	6/15/1998 5:37:00 PM
From: VLAD	Read Replies (1) \| Respond to of 1016

I can give you more than 1. 1)Every stock eventually finds a bottom regardless of technicals or fundamentals. 2)The only new competition is Viagra. Expect nothing else around for a long time. 3)Many do not want to buy until FDA approval is announced. 4)Vivus is working on new products just like everyone else. 5)The patent on the delivery system is worth at least $6.00/share and probably more. 6)The Viagra hype is still not over.

To: MIKE DUBIS who wrote (579)	6/15/1998 8:47:00 PM
From: AlienTech	Respond to of 1016

>>Market condition negative trading behavior of the stock poor script numbers shareholder suits new competition negative publicity as to effectiveness of drug << Amazing.. One of the best setups I have seen. All the crap from last year. I bet some of the biggest bulls who ran the price up last year to 40 are also the biggest shorts on this stock now. How about that bet Mike? Seeing todays price drop and how they did it made me realise that I needed to look at things a little differently to see what the game is here. To think I saw it in the low 20's but when it started pusing towards 40 I though maybe I was mistaken, But not now. The proof's right in front of you if you look. I must say congrats to you mike to see it before I did.. I think AssEncio is the small fish in this game.. rofl..